Results 71 to 80 of about 2,997 (148)

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

, 2017
Dave Singh,1 Mario Scuri,2 Sara Collarini,2 Stefano Vezzoli,2 Fabrizia Mariotti,2 Annamaria Muraro,2 Daniela Acerbi2 1Medicines Evaluation, University Of Manchester, University Hospital of South Manchester, Manchester, UK; 2Global Clinical Development ...
Scuri M, Mariotti F, Acerbi D, Collarini S, Vezzoli S, Singh D, Muraro A   +6 more
core  

Effect of glycopyrronium bromide on basal, and histamine- or gastrin-induced gastric secretion

, 1969
Acid secretory responses were obtained in rats given either intravenous histamine as dihydrochloride or gastrin subjected to partial purification. A continuous recording method for measuring gastric acid secretion was used.
B O Amure
core   +1 more source

Pharmacokinetics of glycopyrronium following repeated once-daily inhalation in healthy Chinese subjects

, 2015
Glycopyrronium is a once-daily long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Hara, Hisanori, Tan, Xuemei, Sechaud, Romain, Zhao, Rong, Tillmann, Hanns-Christian, Ren, Shuang, Machineni, Surendra Kumar, Hou, Jie   +7 more
core   +1 more source

Effect of cimetidine, a model drug for inhibition of the organic cation transport in the kidney, on the pharmacokinetics of glycopyrronium

, 2013
Objective: Glycopyrronium (NVA237), a novel once-daily long-acting muscarinic antagonist (LAMA), has recently been approved for maintenance treatment of COPD.
Drollmann, Anton Franz, Kaiser, Guenther, Sechaud, Romain, Pal, Parasar, Camenisch, Gian P., Dumitras, Swati, Vaidyanathan, Sivakumar   +6 more
core   +1 more source

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY

Медицинский совет, 2016
The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS.
S. N. AVDEEV
doaj   +1 more source

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide

Patient Preference and Adherence, 2019
Erminia Ridolo,1 Irene Pellicelli,1 Bruna Gritti,2 Cristoforo Incorvaia2 1Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy; 2Cardiac/Pulmonary Rehabilitation Unit, ASST Pini-CTO, Milan, Italy Abstract:
Ridolo E, Pellicelli I, Gritti B, Incorvaia C   +3 more
doaj  

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease

Drug Design, Development and Therapy, 2017
Pierachille Santus,1 Dejan Radovanovic,1 Andrea Cristiano,1 Vincenzo Valenti,2 Maurizio Rizzi1 1Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Division of Respiratory Diseases, “L.
Santus P, Radovanovic D, Cristiano A, Valenti V, Rizzi M   +4 more
doaj  

Mini review on different analytical approaches for quantitative analysis of glycopyrronium and indacaterol in various matrices [PDF]

ERU Research Journal
Inhaled bronchodilators are crucial for managing the symptoms of chronic obstructive pulmonary disease (COPD), a progressive lung condition marked by airflow restriction.
Michael Fawzy, Eman Bahgat, Hawa Khalil, Alaa Reda   +3 more
doaj   +1 more source

Glycopyrronium bromide for chronic obstructive pulmonary disease (Protocol)

, 2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To critically appraise the efficacy and safety of glycopyrronium bromide, in terms of objective and subjective measures, in patients with ...
Bowman, Rayleen V., Eastment, Jacques G., Burke, Joseph P, Yang, Ian A., Fong, Kwun M.   +4 more
core   +1 more source

The effect of glycopyrronium inhalation on sialorrhea and drooling in patients with Parkinson's disease [PDF]

, 2018
OBJECTIVE: To investigate the safety and tolerability of glycopyrronium inhalation powder using different dosing regimens and to determine the decrease of drooling in patients with Parkinson's disease. DESIGN: We conducted a 5-week safety study. METHODS:
Masselink, J.B., van Velzen, L., van der Palen, J.A.M.; id_orcid, Dorresteijn, L.D.A., Movig, K.L.L.   +4 more
core   +1 more source